Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
GLYC

GLYC - GlycoMimetics Inc Stock Price, Fair Value and News

$11.27-0.48 (-4.09%)
Market Closed

71/100

GLYC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

71/100

GLYC

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$18.65

Target 3M

$14.07

Target 6M

$15.45

GLYC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GLYC Price Action

Last 7 days

-5.3%

Last 30 days

3.5%

Last 90 days

0.9%

Trailing 12 Months

-52.6%

GLYC RSI Chart

GLYC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

GLYC Valuation

Market Cap

156.6M

Price/Earnings (Trailing)

-1.97

Price/Sales (Trailing)

1.9K

EV/EBITDA

8.49

Price/Free Cashflow

-3.56

GLYC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$18.65

Target 3M

$14.07

Target 6M

$15.45

GLYC Fundamentals

GLYC Revenue

Revenue (TTM)

92.6K

Rev. Growth (Yr)

807.67%

Rev. Growth (Qtr)

308.31%

GLYC Earnings

Earnings (TTM)

-79.4M

Earnings Growth (Yr)

-150.47%

Earnings Growth (Qtr)

-12.93%

GLYC Profitability

EBT Margin

4961.38%

Return on Equity

-68.08%

Return on Assets

-57.43%

Free Cashflow Yield

-28.09%

GLYC Investor Care

Shares Dilution (1Y)

2054.41%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20250000
20240000
20230000
20220179.3K179.2K92.6K
20212.2M2.2M1.3M1.2M
202000010.2M
20190000
20180000
20170000
20160000
2015035.1M20.0M20.1M
201406.8M12.3M15.0M
201312.4M9.6M6.8M4.0M
201200015.3M
Get all data in R, Python etc through our Historical Stock Data APIs

About GlycoMimetics Inc

GLYC
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
 CEO
 WEBSITEglycomimetics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES38

GlycoMimetics Inc Frequently Asked Questions

GLYC is the stock ticker symbol of GlycoMimetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Tue Jan 27 2026, market cap of GlycoMimetics Inc is 156.57 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check GLYC's fair value in chart for subscribers.

The fair value guage provides a quick view whether GLYC is over valued or under valued. Whether GlycoMimetics Inc is cheap or expensive depends on the assumptions which impact GlycoMimetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GLYC.

As of Tue Jan 27 2026, GLYC's PE ratio (Price to Earnings) is -1.97 and Price to Sales (PS) ratio is 1.86 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GLYC PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, GlycoMimetics Inc has provided -0.304 (multiply by 100 for percentage) rate of return.